{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:37:48Z","timestamp":1787841468438,"version":"build-2784847793"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ovarian cancer is one of the most common cancers with a high mortality rate among females worldwide. The understanding of the pathogenesis of the disease is highly important to provide personalized therapy to the patients. Ovarian cancer is as heterogeneous as colon and breast cancer which makes it difficult to treat. The development of gene signature is the only hope in providing targeted therapy to improve the survival of ovarian cancer patients. Malignant epithelial carcinomas are the most common cancers of the ovary with different histological and molecular subtypes and clinical behavior. The development of precursor lesions of ovarian carcinoma in the tubes and endometrium has provided a new dimension to the origin of ovarian cancers. The clinical utility of various gene signatures may not be logical unless validated. Validated gene signatures can aid the clinician in deciding the appropriate line of treatment.<\/jats:p>","DOI":"10.4103\/gmit.gmit_13_23","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T07:03:25Z","timestamp":1721372605000},"page":"141-145","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The Progression and Prospects of the Gene Expression Profiling in Ovarian Epithelial Cancer"],"prefix":"10.4103","volume":"13","author":[{"given":"Banushree Chandrasekhar","family":"Srinivasamurthy","sequence":"first","affiliation":[{"name":"Department of Pathology, Indira Gandhi Medical College and Research Institute, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhashini","family":"Ramamoorthi","sequence":"additional","affiliation":[{"name":"Department of Pathology, JIPMER, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/ijc.30676","article-title":"International patterns and trends in ovarian cancer incidence, overall and by histologic subtype","volume":"140","author":"Coburn","year":"2017","journal-title":"Int J Cancer"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","article-title":"Progress and challenges in screening for early detection of ovarian cancer","volume":"3","author":"Jacobs","year":"2004","journal-title":"Mol Cell Proteomics"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1155\/2007\/309382","article-title":"Early detection of ovarian cancer","volume":"23","author":"Badgwell","year":"2007","journal-title":"Dis Markers"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: Epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int J Womens Health"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3390\/ijms17122113","article-title":"Molecular characterization of epithelial ovarian cancer: Implications for diagnosis and treatment","volume":"17","author":"Rojas","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: A review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"key":"R8-20240830","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.3802\/jgo.2016.27.e25","article-title":"Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial","volume":"27","author":"Terada","year":"2016","journal-title":"J Gynecol Oncol"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.3802\/jgo.2020.31.e70","article-title":"FIGO staging in ovarian carcinoma and histological subtypes","volume":"31","author":"Kehoe","year":"2020","journal-title":"J Gynecol Oncol"},{"issue":"Suppl 2","key":"R10-20240830","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ijgo.12614","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"143","author":"Berek","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2016.01.026","article-title":"Gene-expression signatures in ovarian cancer: Promise and challenges for patient stratification","volume":"141","author":"Konecny","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/sj.bjc.6602238","article-title":"TP53 status determines clinical significance of ERBB2 expression in ovarian cancer","volume":"91","author":"Kupryja\u0144czyk","year":"2004","journal-title":"Br J Cancer"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1091\/mbc.e03-05-0279","article-title":"Gene expression patterns in ovarian carcinomas","volume":"14","author":"Schaner","year":"2013","journal-title":"Mol Biol Cell"},{"key":"R14-20240830","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/241763","article-title":"MDR gene expression analysis of six drug-resistant ovarian cancer cell lines","author":"Januchowski","year":"2013","journal-title":"Biomed Res Int 2013"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1757-2215-6-39","article-title":"Screening of feature genes of the ovarian cancer epithelia with DNA microarray","volume":"6","author":"Ying","year":"2013","journal-title":"J Ovarian Res"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","article-title":"Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome","volume":"14","author":"Tothill","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/emmm.201201823","article-title":"Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer","volume":"5","author":"Tan","year":"2013","journal-title":"EMBO Mol Med"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/path.2547","article-title":"Aprognostic gene expression index in ovarian cancer \u2013 Validation across different independent data sets","volume":"218","author":"Denkert","year":"2009","journal-title":"J Pathol"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"e18064","DOI":"10.1371\/journal.pone.0018064","article-title":"Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers","volume":"6","author":"Helland","year":"2011","journal-title":"PLoS One"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ccr.2009.10.018","article-title":"Agene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: Microfibril-associated glycoprotein 2","volume":"16","author":"Mok","year":"2009","journal-title":"Cancer Cell"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/1055-9965.EPI-18-1359","article-title":"The impact of stroma admixture on molecular subtypes and prognostic gene signatures in serous ovarian cancer","volume":"29","author":"Schwede","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/his.12349","article-title":"Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry","volume":"64","author":"K\u00f6bel","year":"2014","journal-title":"Histopathology"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer \u2013Shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum Pathol"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/ijc.26364","article-title":"Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples","volume":"131","author":"Fekete","year":"2012","journal-title":"Int J Cancer"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1038\/sj.onc.1206865","article-title":"Advantages and limitations of microarray technology in human cancer","volume":"22","author":"Russo","year":"2003","journal-title":"Oncogene"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"52571","DOI":"10.18632\/oncotarget.16732","article-title":"Integrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ccell.2018.03.006","article-title":"lncRNA Epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer","volume":"33","author":"Wang","year":"2018","journal-title":"Cancer Cell"},{"key":"R29-20240830","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1200\/JCO.2004.04.070","article-title":"Gene expression signature with independent prognostic significance in epithelial ovarian cancer","volume":"22","author":"Spentzos","year":"2004","journal-title":"J Clin Oncol"},{"key":"R30-20240830","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1158\/1078-0432.CCR-04-2509","article-title":"Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon","volume":"11","author":"Marquez","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R31-20240830","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-04-2398","article-title":"Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers","volume":"11","author":"Berchuck","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R32-20240830","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/1078-0432.CCR-04-2682","article-title":"Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers","volume":"11","author":"Jazaeri","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R33-20240830","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1158\/0008-5472.CAN-07-6595","article-title":"Agene signature predicting for survival in suboptimally debulked patients with ovarian cancer","volume":"68","author":"Bonome","year":"2008","journal-title":"Cancer Res"},{"key":"R34-20240830","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/GMIT.GMIT_93_18","article-title":"The role of laparoscopy and the value of peritoneal carcinomatosis index in patients with intra-abdominal malignancies who are scheduled to laparotomy","volume":"8","author":"Wang","year":"2019","journal-title":"Gynecol Minim Invasive Ther"},{"key":"R35-20240830","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4103\/GMIT.GMIT_59_18","article-title":"Is it the time for laparoscopic management of early-stage ovarian malignancies?","volume":"7","author":"Tantitamit","year":"2018","journal-title":"Gynecol Minim Invasive Ther"},{"key":"R36-20240830","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/GMIT.GMIT_2_19","article-title":"Role of frozen section in surgical management of ovarian neoplasm","volume":"9","author":"Palakkan","year":"2020","journal-title":"Gynecol Minim Invasive Ther"},{"key":"R37-20240830","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1371\/journal.pmed.1000024","article-title":"Survival-related profile, pathways, and transcription factors in ovarian cancer","volume":"6","author":"Crijns","year":"2009","journal-title":"PLoS Med"},{"key":"R38-20240830","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/GMIT.GMIT_79_20","article-title":"The roles of microRNA-133 in gynecological tumors","volume":"11","author":"Zhou","year":"2022","journal-title":"Gynecol Minim Invasive Ther"},{"key":"R39-20240830","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"R40-20240830","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/bjc.2011.219","article-title":"Aseven-gene prognostic model for platinum-treated ovarian carcinomas","volume":"105","author":"Sabatier","year":"2011","journal-title":"Br J Cancer"},{"key":"R41-20240830","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/jnci\/djs177","article-title":"A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy","volume":"104","author":"Kang","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"R42-20240830","first-page":"517","article-title":"Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","volume":"123","author":"Verhaak","year":"2013","journal-title":"J Clin Invest"},{"key":"R43-20240830","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju249","article-title":"Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer","volume":"106","author":"Konecny","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R44-20240830","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/bjc.2016.124","article-title":"Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer","volume":"114","author":"Wang","year":"2016","journal-title":"Br J Cancer"},{"key":"R45-20240830","doi-asserted-by":"crossref","first-page":"9689","DOI":"10.1038\/s41598-017-08766-5","article-title":"The prognostic 97 chemoresponse gene signature in ovarian cancer","volume":"7","author":"Matondo","year":"2017","journal-title":"Sci Rep"},{"key":"R46-20240830","first-page":"1755","article-title":"Identification of an energy metabolism-related gene signature in ovarian cancer prognosis","volume":"43","author":"Wang","year":"2020","journal-title":"Oncol Rep"},{"key":"R47-20240830","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.annonc.2020.05.019","article-title":"Prognostic gene expression signature for high-grade serous ovarian cancer","volume":"31","author":"Millstein","year":"2020","journal-title":"Ann Oncol"},{"key":"R48-20240830","doi-asserted-by":"crossref","first-page":"e9615","DOI":"10.1371\/journal.pone.0009615","article-title":"Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets","volume":"5","author":"Yoshihara","year":"2010","journal-title":"PLoS ONE"},{"key":"R49-20240830","first-page":"1","article-title":"Bioinformatics analysis of gene expression profile of serous ovarian carcinomas to screen key genes and pathways","volume":"13","author":"Fei","year":"2020","journal-title":"J of Ovar Res"}],"container-title":["Gynecology and Minimally Invasive Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/gmit.gmit_13_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:56:17Z","timestamp":1787838977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/gmit.gmit_13_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/gmit.gmit_13_23","relation":{},"ISSN":["2213-3070","2213-3089"],"issn-type":[{"value":"2213-3070","type":"print"},{"value":"2213-3089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2023-01-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}